A multicenter analysis to identify the risk factors for stroke recurrence and mortality within 1 year

一项多中心分析,旨在确定一年内卒中复发和死亡的风险因素。

阅读:1

Abstract

BACKGROUND: Stroke recurrence is a serious and prevalent complication of ischemic stroke that warrants additional investigation. METHODS: A hospital-based retrospective observational study included acute-subacute ischemic stroke adult patients. The primary aim was to determine the risk factors associated with recurrent stroke within 365 days. Additionally, a combined outcome consisting of any stroke recurrence or all-cause mortality within 365 days was considered secondary outcome. Univariate and multivariable Cox proportional-hazards models were used to examine the association of risk factors with stroke recurrence and composite death/stroke recurrence. RESULTS: Of 1,244 patients, 112 (9%) experienced stroke recurrence. The multivariable analysis identified risk factors for stroke recurrence including history of previous stroke (HR = 3.65, 95% CI:2.28-5.99, p = 0.0001), tissue plasminogen activator (tPA) treatment (HR = 2.84, 95% CI:1.57-4.86, p = 0.0003), seizure (HR = 1.96, 95% CI:1.14-3.22, p = 0.0105), and depression (HR = 2.26, 95% CI:1.33-3.69, p = 0.0016). Only previous stroke history (HR = 2.37, 95% CI:1.74-3.26, p = 0.0001) remained significantly associated with the combined outcome of stroke recurrence/death. Additional risk factors for the composite outcome included older age of patients (HR = 1.02, 95% CI:1.01-1.03, p = 0.0009), admission to the intensive care unit (ICU) (HR = 3.70, 95% CI:2.63-5.22, p = 0.0105), pneumonia (HR = 1.47, 95% CI:1.05-2.05, p = 0.0249), and brain edema (HR = 2.36, 95% CI:1.58-3.46, p = 0.0001). CONCLUSION: Key findings include a stroke recurrence rate of 9.96% and a combined death/stroke recurrence rate of 21.83% within 365 days. Multivariable analysis confirmed that history of stroke, receiving tPA, experiencing seizures, and depression were significantly associated with stroke recurrence. Implementing additional preventive measures for individuals in these high-risk categories is essential. Further studies are needed to validate our findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。